Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will report its third quarter 2021 financial results on November 15, 2021. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a business update. The company focuses on developing innovative therapies for eye diseases using its AMPPLIFY® mucus-penetrating particle Drug Delivery Technology. Its key products include EYSUVIS® for dry eye disease and INVELTYS® for post-operative inflammation following ocular surgery. Further details and the live webcast are available on Kala's website.

Positive

• Scheduled reporting of Q3 2021 financial results indicates transparency and engagement with shareholders.
• The focus on innovative eye disease therapies shows potential for future growth and market relevance.

Negative

• None.

WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2021 financial results on Monday, November 15, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:30 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7298039. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS^® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

When will Kala Pharmaceuticals report its Q3 2021 financial results?

Kala Pharmaceuticals will report its Q3 2021 financial results on November 15, 2021.

What time is the conference call for Kala Pharmaceuticals' Q3 results?

The conference call to discuss Kala Pharmaceuticals' Q3 results is scheduled for 8:30 a.m. ET.

What are the main products developed by Kala Pharmaceuticals?

Kala Pharmaceuticals' main products include EYSUVIS® for dry eye disease and INVELTYS® for post-operative inflammation.

How can I access the conference call for Kala Pharmaceuticals?

You can access the conference call by dialing 866-300-4091 (domestic) or 703-736-7433 (international) with conference ID 7298039.